Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: J Hosp Med. 2015 Feb 13;10(6):358–365. doi: 10.1002/jhm.2329

Table 3.

Variation in testing, hospitalization, and ceftriaxone use based on CPG specific recommendations among infants 29-56 days of age with diagnosis of fever.

Testing / Hospitalization Hospitals, n Patients, n % Received1 aOR (95% CI)2 P-value2
Laboratory Testing
Urine testing3
    No CPG 17 2460 81.1 Ref
    CPG: Recommend for all 16 3772 82.1 0.9 (0.7 - 1.4) 0.76
Blood testing4
    No CPG 17 2460 79.4 Ref
    CPG: Recommend for all 15 3628 82.6 1.1 (0.7 - 1.6) 0.70
    CPG: Recommend consider 1 144 62.5 0.4 (0.3 - 0.7) 0.001
CSF testing5
    No CPG 17 2460 46.3 Ref
    CPG: Recommend for all 8 1517 70.3 1.3 (0.9 - 1.9) 0.11
    CPG: Recommend if high-risk 8 2255 39.9 0.5 (0.3 - 0.8) 0.002
Disposition
Hospitalization
    No CPG 17 2460 47.0 Ref
    CPG: Recommend if high-risk 16 3772 42.0 0.7 (0.5 - 1.1) 0.10
Ceftriaxone if discharged6
    No CPG 17 1304 11.7 Ref
    CPG: Recommend against 4 313 10.9 0.3 (0.1 - 0.9) 0.03
    CPG: Recommend consider 9 1567 14.4 1.5 (0.9 - 2.4) 0.09
    CPG: Recommend for all 3 306 64.1 4.6 (2.3 - 9.3) < 0.001

Abbreviations: CPG, clinical practice guideline; OR, odds ratio; CI, confidence interval; CSF, cerebrospinal fluid

1

% of infants who received test, were hospitalized, or received ceftriaxone

2

Adjusted for hospital clustering, geographic region, payer, race, and gender

3

Urine testing defined as urine dipstick, urinalysis, or urine culture

4

Blood testing defined as CBC or blood culture

5

CSF testing defined as cell count, culture, or procedure code for lumbar puncture

6

For low-risk infants discharged from the ED